Tag Archives: Industry Analysis

IPO update: 28 IPOs, 24 on Deck

The number of IPOs slowed during the summer, but the queue has been filling nicely.  Fifteen more biotechs have filed to go public in the last month and a half, bringing the total to 24 globally. The two US IPOs this summer were from NuPATH and Trius. Again, we saw a reduction in the amount planned vs actually raised for these IPOs. On average, US biotechs have raised an amount 28% below what is first Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

1Q Cash Spending – Small Biotechs Still Spending Less

A comparison of cash spent on operations in the 1st quarter of 2010 vs the 1st quarters of 2009 and 2008 for small public biotechs shows a slowing in the precipitous drop seen over the last 2 years. However, the average small biotech is still spending less cash vs. 2008. When compared to 1Q08, the median cash flow from operations (CFO) in 1Q10 is down -40%. From 1Q09, median CFO is down -15%. See chart Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Biotech Sector Performance Update 1H 2010

In my last update back in April, the broadest Biotech index (the 125 company Nasdaq Biotech Index, NBI) was up 11% for the year and ahead of just about every major sector. One quarter later things look a little different. The NBI is now down 5% and trailing 4 of the 10 S&P sectors (chart 1): However, the spotlight continues to shine on the AMEX Biotech Index (BTK). The BTK is up 8.6% for the Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , ,

2010 BIO Business Forum Partnering Results

2010 BIO Business Forum in Chicago was a huge success last week. We hit record numbers for the three day event making this the single largest partnering event ever held. Our updated 1×1 partnering software system received over 107,000 requests for meetings that resulted in over 17,000 meetings. To put that in perspective, 10 years ago there were only 300 meetings, yielding an explosive 43% CAGR for partnering at the BIO International Convention.  The meetings were set up by some 2,100 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

1Q 2010 – All Time High for the BTK

The first quarter of 2010 saw the Amex Biotech Index (BTK) hit another all time high, thanks largely to Intermune’s (ITMN) jump of 240% and OSI’s (OSIP) gain of 92%. (Intermune received a positive recommendation from an FDA panel for pirfenidone, and OSI’s stock moved on the $3.5B hostile bid from Astellas.) The Nasdaq Biotech Index (NBI) climbed to its highest in over eight years. Both of these biotech indices are up since the financial Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,